Valuation: Pluristem Therapeutics

Market Cap 22.55M 19.31M 18.01M 16.53M 31.06M 2.16B 31.67M 214M 83.31M 1.08B 84.67M 82.83M 3.58B P/E 2024
-1.45x
P/E 2025 -1.39x
Enterprise Value 35.99M 30.81M 28.75M 26.38M 49.57M 3.44B 50.54M 341M 133M 1.73B 135M 132M 5.71B EV / Sales 2024
93.2x
EV / Sales 2025 39.1x
Free-Float
53.43%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 54 28/03/2017
Director of Finance/CFO 42 30/11/2022
Chief Operating Officer - 31/12/2024
Director TitleAgeSince
Director/Board Member 54 31/01/2015
Director/Board Member 56 05/01/2021
Director/Board Member 64 31/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
+3.38%-1.33% - - 18.99M
+1.14%+2.27%+2.38%+24.14% 50.5B
-1.36%+4.82%+485.55%+614.84% 46.01B
-2.04%+3.69%+19.34%+91.23% 42.85B
+2.72%+6.02%+33.33%+19.66% 41.03B
0.00%-3.91%+18.49%+47.98% 32.02B
+0.72%+5.27%+31.55%+145.37% 16.98B
-1.85%+3.48% - - 17.05B
+3.06%+3.88%+5.81%+35.00% 14.3B
+0.50%+3.62%+82.64%+46.53% 13.84B
Average +0.63%+2.92%+84.89%+128.09% 30.51B
Weighted average by Cap. +0.18%+2.74%+104.88%+152.88%

Financials

2024 2025
Net sales 326K 279K 260K 239K 449K 31.19M 458K 3.09M 1.2M 15.63M 1.22M 1.2M 51.75M 1.34M 1.14M 1.07M 979K 1.84M 128M 1.88M 12.66M 4.94M 64.07M 5.02M 4.91M 212M
Net income -20.89M -17.88M -16.69M -15.31M -28.77M -2B -29.34M -198M -77.17M -1B -78.43M -76.72M -3.32B -22.58M -19.34M -18.04M -16.55M -31.11M -2.16B -31.72M -214M -83.43M -1.08B -84.79M -82.95M -3.59B
Net Debt -373K -319K -298K -273K -514K -35.69M -524K -3.53M -1.38M -17.89M -1.4M -1.37M -59.22M 13.44M 11.5M 10.73M 9.85M 18.51M 1.29B 18.87M 127M 49.64M 644M 50.45M 49.36M 2.13B
Logo Pluristem Therapeutics
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-